Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Development of S-Layer Based Vaccines and Cellular Therapeutics
December 30, 2020 09:00 ET
|
Avalon GloboCare Corp.
Aiming to accelerate the clinical development of S-layer nanotechnology for mucosal vaccines, hemo-filtration devices, cell-based therapies and other medical applicationsEstablishing state-of-the-art...
Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point-of-Care Antibody Rapid Test Devices
October 22, 2020 08:30 ET
|
Avalon GloboCare Corp.; Adial Pharmaceuticals, Inc.
FREEHOLD, N.J. and CHARLOTTESVILLE, Va., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (“Avalon”), a clinical-stage, global developer of cell-based technologies and...
Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial
October 01, 2020 09:00 ET
|
Avalon GloboCare Corp.
Expanded AVA-001 CAR T-cell therapy clinical trial to include enrollment of patients with relapsed/refractory non-Hodgkin lymphomaCompleted pre-clinical study and standardized process development for...
Avalon GloboCare CEO to Participate in Virtual Panel: “New Approaches to COVID-19: Hidden Breakthroughs,” on Thursday, September 10th
September 03, 2020 11:11 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare Announces Mesenchymal Stromal Cell Therapeutic Platform for COVID-19 and Acute Graft Versus Host Disease (aGVHD)
September 03, 2020 09:00 ET
|
Avalon GloboCare Corp.
Progressing planned pre-clinical testing for innovative allogeneic MSC-based cellular therapy for both COVID-19 and aGVHD FREEHOLD, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp....
Avalon GloboCare Announces Commercialization and Distribution Agreement with Cellex for COVID-19 Antibody Rapid Test Kit
August 19, 2020 09:00 ET
|
Avalon GloboCare Corp.
FREEHOLD, N.J., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today...
Avalon GloboCare Expands AVA-Trap™ Program to Treat COVID-19 and CAR-T Related Cytokine Storms
August 12, 2020 09:00 ET
|
Avalon GloboCare Corp.
Expands and files two USPTO provisional patent applications jointly with the Massachusetts Institute of Technology (MIT) Media Lab to develop a cytokine-specific blood purification system based on...
Avalon GloboCare Provides Updates on its Lead Scientific and Clinical Programs in CAR T-Cell Therapy and COVID-19
July 13, 2020 09:00 ET
|
Avalon GloboCare Corp.
Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia; Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or...
Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
June 29, 2020 09:30 ET
|
Avalon GloboCare Corp.
- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity...
Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
June 25, 2020 09:00 ET
|
Avalon GloboCare Corp.
- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel...